Pharmaceuticals

Sterne Kessler works with branded pharmaceutical companies as well as biosimilars and generic drug companies to protect, enforce, and defend their intellectual property.

Sterne Kessler's pharmaceuticals practice integrates deep technical knowledge with legal acumen to develop robust patent portfolios, address patent validity challenges at the PTAB, and handle high-profile patent litigation, including Abbreviated New Drug Application (ANDA) and Biologics Price Competition and Innovation Act (BPCIA) matters. We work effectively with our clients to align IP with corporate strategy, and understand the advancements in life sciences that are shaping the IP landscape. Prescription & OTC Drugs Our pharmaceuticals team helps small molecule drug companies across the full range of IP—from patent prosecution and strategy, to opinions and litigation. Infectious Disease Treatments Sterne Kessler protects and defends drug and vaccine innovations developed to fight against infectious diseases. Generic Drug Development We work with generic drug developers to navigate the interface between patent law and the FDA approval process, as well as patent litigation and Abbreviated New Drug Application (ANDA) matters.

Related News & Insights

Speaking Engagement

December 5, 2022 9:30 AM - 10:30 AM PST

Patents in the Cross-Hairs of the Affordable Drug Conversation

Firm Announcements

December 5, 2022

Law Students Invited to Enter Sterne Kessler IP Law Writing Competition $10,000 To Be Awarded as Top Prize

Sterne, Kessler, Goldstein & Fox

In the News

December 2, 2022

Ex-Parte Reexams Drop After Fintiv Change but Still Seen As Useful

Managing IP